louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06877884: A Prospective Registry to Enable Collection of Standardized Routine Care Oncology Patient Data
Official title: A Prospective Registry for Collecting Standardized, Routine Care Data to Characterize Patients, Treatment Patterns, Safety and Treatment Effectiveness in Adult Oncology Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cancer
Lead sponsor: N-Power Medicine
Sponsor class: INDUSTRY
First posted: 2025-03-14
Enrollment: 20000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients at oncology sites participating in the registry.

Brief summary: This is an observational registry for patients at participating oncology centers. The data collection includes but is not limited to baseline variables, treatments given and outcome data. Patient surveys are also included. The aim of the study is to generate rich and standardized data for patients and to help enable more patients participate in clinical trials and contribute to research and development.

Detailed description: This is an observational registry for patients at participating oncology centers. The data collection includes but is not limited to baseline variables, treatments given and outcome data. Patient surveys are also included. The aim of the study is to generate rich and standardized data for patients and to help enable more patients participate in clinical trials and contribute to research and development.

Eligibility criteria: Inclusion Criteria:

Be a patient at a site (oncology) participating in the Registry Be at least 18 years old Be able and willing to provide signed informed consent

Exclusion Criteria:

Prisoners/imprisonment at time of screening for eligibility Patients who cannot consent without utilization of a legally authorized representative

Primary outcomes:
measure: Treatment Effectiveness - Time to treatment discontinuation
timeFrame: This is an open-ended registry where data will be collected, analysed and presented regularly over time.
Secondary outcomes:
Other outcomes:
Locations:
city: Monterey
country: United States
facility: Pacific Cancer Care
state: California
city: Elk Grove Village
country: United States
facility: Northwest Oncology & Hematology
state: Illinois
city: Albuquerque
country: United States
facility: New Mexico Oncology Hematology Consultants
state: New Mexico
city: Houston
country: United States
facility: Oncology Consultants, P.A.
state: Texas
Study officials:
References:
Clinical trial NCT01514084: Cosmetic Outcomes and Patient Satisfaction After Facial Laceration Repair in the Emergency Department
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Facial Lacerations
Keywords: laceration
emergency
cosmetic outcomes
patient satisfaction
suture
Lead sponsor: Children's Hospitals and Clinics of Minnesota
Sponsor class: OTHER
First posted: 2012-01-20
Enrollment: 160
Sex: ALL
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pediatric emergency department

Brief summary: Facial lacerations are commonly treated in the emergency department. The nature of the injury leads to a great deal of concern about the long-term cosmetic appearance of the wounds.

Research Questions

1. What is the association between wound characteristics, wound management in the ED, patient satisfaction in the ED, and patient-rated cosmetic appearance of sutured wounds?
2. Is there a difference noted among ED providers with different levels of training?
3. Is there an association between initial satisfaction scores and wound outcome?
4. Is there an association between short term and long term wound scores?

Design This is a non-randomized, prospective, observational study of patients who present to the ED seeking treatment for facial laceration repair.


Eligibility criteria: Inclusion Criteria:

* Families presenting to the ED for repair of facial laceration will be approached for study inclusion if:

  * Their child seeking treatment is less than 18 years of age
  * The laceration was sustained less than 12 hours prior to presentation to Children's ED
  * They speak English

Exclusion Criteria:

* Families presenting to the ED for repair of facial laceration will be excluded from study participation if they:

  * Are medically complex children
  * Have a history of pre-existing coagulopathy or collagen vascular disease
  * Have a history of immunodeficiency or diabetes mellitus
  * Are suspected of non-accidental trauma
  * Have wounds that could be approximated by tissue adhesives
  * Have animal or human bites
  * Have gross contamination
  * Have puncture wounds
  * Have lacerations of tendon/nerve/cartilage
  * Have scalp lacerations
  * Do not speak English

Primary outcomes:
measure: Cosmetic outcome
timeFrame: 6 months
Secondary outcomes:
measure: Satisfaction score
timeFrame: 6 months
Other outcomes:
Locations:
city: Twin Cities
country: United States
facility: Children's Hospitals and Clinics of Minnesota
state: Minnesota
Study officials:
References:
citation: Quinn JV, Wells GA. An assessment of clinical wound evaluation scales. Acad Emerg Med. 1998 Jun;5(6):583-6. doi: 10.1111/j.1553-2712.1998.tb02465.x.
Clinical trial NCT04892784: THE EFFECT OF ACUPUNCTURE ON THE BLOOD LACTIC ACID LEVELS
Official title: THE EFFECT OF PRESS TACK NEEDLE ACUPUNCTURE ON THE REDUCTION OF POST-EXERCISE BLOOD LACTIC ACID LEVELS IN SPORT STUDENTS
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Post-exercise Sport Students
Keywords: acupuncture
lactic acid levels
post-exercise recovery
press tack needle
Lead sponsor: Indonesia University
Sponsor class: OTHER
First posted: 2021-05-19
Enrollment: 24
Sex: MALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Background: In sports, recovery after exercise is a very important process for athletes. Several studies have shown that the rate of disease associated with athlete's recovery can be increased by several modalities, one of which is acupuncture.

Objectives: The purpose of this study was to see how the effect of press tack needle acupuncture in reducing blood lactic acid levels after exercise in sports students.

Methods: The study design was a randomized controlled clinical trial. Twenty-four sport students were divided into two groups: the acupuncture group (n = 12) and the normal group (n = 12). Press tack needle was attached on PC6 Neiguan and ST36 Zusanli 30 minutes before doing high-intensity exercise. Measurement of lactic acid levels was carried out at 5 minutes and 30 minutes after exercise.


Eligibility criteria: Inclusion Criteria:

* willingness to fill out an informed consent form;
* age between 18-25 years;
* male;
* has a BMI value of 18.5-22.9 kg/m2;
* there is no history of injury or history of surgery on the lower extremities in the last three months;
* the individual is in good health.

Exclusion Criteria:

* absence or refusal to be examined and not cooperative.

Primary outcomes:
measure: Lactic acid levels
timeFrame: 5-minute after physical exercise and 30-minute after physical exercise
Secondary outcomes:
measure: Heart rate
timeFrame: 0-minute after physical exercise and 30-minute after physical exercise
Other outcomes:
Locations:
city: Jakarta
country: Indonesia
facility: Fakultas Ilmu Keolahragaan Universitas Negeri Jakarta
Study officials:
References:
Clinical trial NCT06971484: Glucosamine Sulfate Bioavailability
Official title: Comparative Bioavailability of Crystalline and Regular Glucosamine Sulfate: A Randomized Crossover Study in Healthy Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bioavailability and Pharmacokinetics
Keywords: glucosamine
crystalline
pharmacokinetics
bioavailability
Lead sponsor: Isura
Sponsor class: OTHER
First posted: 2025-05-14
Enrollment: 10
Sex: ALL
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study aims to compare the pharmacokinetics and bioavailability of crystalline glucosamine sulfate and regular glucosamine sulfate using a double-blind, randomized, crossover design.


Eligibility criteria: Inclusion Criteria:

* Male or female aged 21- 65 years
* Healthy, good physical condition
* Voluntary, written, informed consent to participate in the study.

Exclusion Criteria:

* Serious acute or chronic diseases e.g. liver, kidney, or gastrointestinal diseases
* Use of medications affecting glucosamine metabolism
* Known allergies to shellfish or glucosamine
* Pregnancy or breastfeeding
* Participation in another investigational study

Primary outcomes:
measure: AUC: the area under the concentration-time curve
timeFrame: 0 (baseline; pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 hours (post-dose)
measure: Cmax: maximum plasma concentration
timeFrame: 0 (baseline; pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 hours (post-dose)
measure: Tmax: the time point of maximum plasma concentration
timeFrame: 0 (baseline; pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 12, 24 hours (post-dose)
Secondary outcomes:
Other outcomes:
Locations:
city: Burnaby
country: Canada
facility: ISURA
state: British Columbia
Study officials:
References:
Clinical trial NCT01627184: Long-term Use: CGM System Assessment in Adult Athletes With Diabetes Mellitus
Official title: Long-term Use: CGM System Assessment in Adult Athletes With Diabetes Mellitus
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus
Lead sponsor: DexCom, Inc.
Sponsor class: INDUSTRY
First posted: 2012-06-25
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult athletes with diabetes mellitus

Brief summary: The purpose of this study is to evaluate CGM glycemic control using the Dexcom G4 system as well as system performance during high levels of activity and home use by adult athletes with insulin-requiring diabetes mellitus, over an extended period of time.


Eligibility criteria: Inclusion Criteria:

1. Age 18 years or older
2. Diagnosis of diabetes mellitus

Exclusion Criteria:

1. Extensive skin changes/diseases
2. Known allergy to medical adhesives
3. Pregnancy
4. Dialysis

Primary outcomes:
measure: Glycemic Control during Exercise
timeFrame: multiple months, up to 6
Secondary outcomes:
measure: System Utility and Usability
timeFrame: multiple months, up to 6
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Atlanta Diabetes Association
state: Georgia
Study officials:
References:
Clinical trial NCT02313584: Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Atrial Fibrillation
Thromboembolism
Keywords: dabigatran
Lead sponsor: Korea University
Sponsor class: OTHER
First posted: 2014-12-10
Enrollment: 464
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to investigate the appropriate duration of dabigatran use after radiofrequency catheter ablation for paroxysmal atrial fibrillation in patients with low thromboembolic risk. According to the most recent guideline, anticoagulation is recommended to continue at least 2 months after the procedure. However bleeding risk with anticoagulant is also problematic. Post-procedural thrombosis is considered due to acute inflammation or char formation at the site of ablation, and these reaction occurs mostly within 1 month after the procedure. Also, the risk of thromboembolism is low in patients with CHA2DS2-VASc score less than 1. The investigators hypothesized that dabigatran use for the first 1 month after the RFCA for patients with paroxysmal AF and low thromboembolic risk would be sufficient for efficacy and safety compared to conventional dabigatran use for 2 months.


Eligibility criteria: Inclusion Criteria:

* paroxysmal AF undergoing catheter ablation
* CHA2DS2-VASc score \<= 1
* informed consent

Exclusion Criteria:

* persistent AF
* CHA2DS2-VASc score \> 2
* prior CVA
* prior atnicoagulant
* severe HF
* abnormal liver or renal function
* history of severe bleeding

Primary outcomes:
measure: The rate of thromboembolic events
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06520384: Radiofrequency Applications and Alcoholic Neurolysis of Genicular Nerve for the Treatment of Knee Osteoarthritic Pain
Official title: Comparison of Radiofrequency Applications and Alcoholic Neurolysis of Genicular Nerve for the Treatment of Knee Osteoarthritic Pain: A Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Radiofrequency
Alcohol
Genicular Nerve
Knee Osteoarthritis
Pain
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2024-07-25
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to investigate the efficacy of radiofrequency ablation and alcoholic neurolysis of genicular nerve on alleviating pain and improving the function of advanced knee osteoarthritis patients.

Detailed description: Knee osteoarthritis (OA) is a major cause of pain and disability. Patients with moderate to severe knee OA often suffer from excruciating pain with chronic inflammation and reduced range of motion.

Conventional treatment of knee OA includes nonpharmacologic therapies and pharmacologic therapies. Analgesics, low-potency opioids, narcotic analgesics, and nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used in pharmacologic therapies.

Radiofrequency ablation (RFA) has been used for the treatment of chronic pain that has been unresponsive to conservative therapies. It acts by disrupting the transmission of pain signals using thermal lesion production to interrupt nociceptive signals.

The nerve block is conventionally performed by local anesthesia alone or in combination with corticosteroid. Nerve ablation causes iatrogenic neural degeneration aiming only for sensory or sympathetic denervation without motor deficits. The nerve ablation methods currently available are performed by either thermal ablation using RFA or chemical ablation using alcohol or phenol.

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years old.
* Both sexes.
* Patients with knee osteoarthritis.
* Previous conservative treatments longer than 3 months.
* visual analog scale (VAS)≥ 4.
* Radiological osteoarthritis grades 3 and 4 according to the Kellgren-Lawrence grading system (0 = none, 1 = doubtful, 2 = minimal, 3 = moderate, and 4 = severe).

Exclusion Criteria:

* Patient refusal.
* History of knee surgery.
* Radiculopathy.
* Anticoagulant therapy.
* Injection with steroids or hyaluronic acids during the previous 3 months.
* Serious neurologic or psychiatric disorders.

Primary outcomes:
measure: Degree of knee pain
timeFrame: 6 months postoperative
Secondary outcomes:
measure: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores
timeFrame: 6 months postoperative
measure: Patient satisfaction
timeFrame: 6 months postoperative
measure: Incidence of adverse events
timeFrame: 6 months postoperative
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University
state: El-Gharbia
Study officials:
References:
Clinical trial NCT02242084: Thrombolysis in Ischemic Spinal Cord Stroke
Official title: Thrombolysis in Ischemic Spinal Cord Stroke
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Motor Weakness in Two or Four Limbs
Damage in the Anterior Spinal Artery (ASA)
Temperature and Superficial Sensation
Urinary Retention or Bowel Disorder
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2014-09-16
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Ischemic stroke of the spinal cord is a rare disease accounting for about 1% of all ischemic events in the central nervous system (CNS). In most cases the consequences are catastrophic, with a high rate of severe functional disability and mortality rate up to 30%.

Ischemic stroke of the spinal cord can arise from:

1. Dissection of the aorta.
2. Aneurism in the aorta.
3. Atherosclerotic disease of the aorta or vertebral arteries.
4. Spinal surgeries.
5. Spinal AVM.
6. Embolism from cardiac origin.
7. Occlusion of radicular artery. Onset is usually sudden, reaching maximal intensity in hours until the patient becomes paralyzed in two or in all four limbs. In most cases the damage is in the Anterior Spinal Artery (ASA). The disease is expressed with motor weakness accompanied by disturbance of temperature and superficial sensation, urinary retention or bowel disorder, with preserved position and vibration sense.

The differential diagnosis of ischemic spinal cord includes diseases such as acute myelitis of the spinal cord or acute demyelinating polyneuropathy like Guillan Barree Syndrome (GBS). Therefore in order to reach the appropriate diagnosis in most cases an urgent MRI of the spinal cord is necessary upon arrival in the emergency department.

One of the treatments to acute ischemic stroke is providing thrombolysis. As tested and validated in numerous studies for ischemic events in the brain, until today no validated study in ischemic spinal stroke using thrombolysis has been completed.


Eligibility criteria: Inclusion Criteria:

1. Patients with vascular risk factors
2. Patients with sudden weakness of the lower or upper limbs together with bowel disorder.
3. Window treatment - not over 6 hours since the start of the event till the start of the treatment.
4. Patient without dissection of the aorta in the abdomen.
5. Patient without contraindication to IVtPA.
6. Patient with no etiology found after clarification.

Exclusion Criteria:

1. Refusal to sign an ICF. 2. Reason for weakness is known. 3. Patient with contraindication IVtPA.

-

Primary outcomes:
measure: Modified Ranking Scale (mRS)
timeFrame: 3 month post thrombolysis
Secondary outcomes:
Other outcomes:
Locations:
city: Petach Tiqva
country: Israel
facility: Rabin Medical Center
state: Hamerkaz
Study officials:
affiliation: Rabin Medical Center
name: Israel Steiner, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01653184: Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration
Official title: The Effect of Oral Supplementation With Omega-3 Fatty Acids on Serum Omega-3 Levels in Patients With Age-related Macular Degeneration: A Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Macular Degeneration
Keywords: AMD
Vision loss
omega-3
supplement
age related macular degeneration
Lead sponsor: Wills Eye
Sponsor class: OTHER
Collaborators: name: Physician Recommended Nutriceuticals
First posted: 2012-07-30
Enrollment: 30
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The effect of omega-3-fatty acids on blood levels omega-3 fatty acids in patients with age-related macular degeneration.

Detailed description: There is observational data in the current literature suggesting that the intake of foods high in marine sources of omega-3 fatty acids, such as fish, may lower the risk of developing age-related macular degeneration (AMD). A large prospective study is underway to determine whether oral supplementation with 1 gram of omega-3 fatty acids is beneficial for subjects with dry AMD. The purpose of our study is to evaluate the change in serum omega-3 index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid supplementation versus 2 grams.

Eligibility criteria: Inclusion Criteria:

* Ability to provide written informed consent and comply with study assessments for the full duration of the study.
* Have AREDS category 3 or 4 disease.
* Category 3: Many medium sized drusen or one or more large drusen in one or both eyes
* Category 4: Geographic atrophy or choroidal neovascularization in one eye.

Exclusion Criteria:

* Women of child-bearing age with positive urine pregnancy tests or desire to conceive during the course of the study.
* Patients with a known fish allergy.
* Patients currently taking supplementation with omega-3 fatty acids and have an omega-3 index of greater than 4%.

Primary outcomes:
measure: Change in omega-3 index
timeFrame: Monthly for 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cherry Hill
country: United States
facility: Mid Atlantic Retina- Cherry Hill
state: New Jersey
city: Bethlehem
country: United States
facility: Mid Atlantic Retina - Bethlehem
state: Pennsylvania
city: Huntingdon Valley
country: United States
facility: Mid Atlantic Retina- Hungtindon Valley
state: Pennsylvania
city: Philadelphia
country: United States
facility: Mid Atlantic Retina- Wills Eye Institute
state: Pennsylvania
Study officials:
affiliation: Mid Atlantic Retina
name: Mitchell Fineman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00284284: Investigation of the Added Value of a Big Toe Hinged Brace for the Treatment of Hallux Rigidus
Official title: Investigation of the Added Value of a Big Toe Hinged Brace for the Treatment of Hallux Rigidus
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Hallux Rigidus
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2006-01-31
Enrollment: 0
Sex: ALL
Minimum age (years): 40
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Comparison of the added value of a rehabilitation brace to standard rehabilitation by physiotherapy


Eligibility criteria: Inclusion Criteria:

* Hallux rigidus

Exclusion Criteria:

-

Primary outcomes:
measure: Mobility of the big toe joint
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital, Ghent
name: Rene Verdonk, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: